Castleman 疾病治療市場：依疾病類型、適應症、治療方法、用途- 全球預測 2023-2030

預計2023年全球Castleman病治療市場將達2.8518億美元，複合年成長率為14.65%，大幅成長，2030年將達到7.4387億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球卡斯爾曼病治療市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1. Castleman病治療的全球市場規模和預測是多少？

2.在預測期內，COVID-19 對全球卡斯爾曼疾病治療市場的阻礙因素與影響為何？

3.預測期內全球卡斯爾曼病治療市場需要投資哪些產品/細分市場/應用/領域？

4. Castleman病治療全球市場的競爭策略是什麼？

5. 全球Castleman疾病治療市場的技術趨勢和法律規範是什麼？

6.全球Castleman疾病治療市場主要廠商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入 Castleman 病治療的全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • Castleman病的診斷進展
    • 愛滋病患者中卡斯爾曼病的罹患率增加
    • 人們對卡斯爾曼病的認知不斷提高
  • 抑制因素
    • 藥品溢價
  • 機會
    • 政府對孤兒藥研發的支持
    • 特發性多中心 Castleman 病預測生物標記的潛力
  • 任務
    • 有關目前臨床試驗的資訊有限
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化
  • 首選治療方案

第6章 卡斯爾曼疾病治療市場：依疾病類型

• 多中心卡斯爾曼病
• 單中心卡斯爾曼病

第7章 卡斯爾曼疾病治療市場（按適應症）

• 血管濾泡淋巴結增生
• 血管瘤性淋巴瘤
• 卡斯特曼瘤
• 巨大良性淋巴瘤
• 巨大淋巴結增生
• 淋巴錯構瘤

第8章 卡斯爾曼疾病治療市場（依療法）

• 抗病毒藥物
• 化學處理
• 皮質類固醇
• 免疫療法
• 單株抗體
• 放射治療

第9章 卡斯爾曼疾病治療市場：依用途

• 門診手術中心
• 醫院

第10章 美洲卡斯爾曼疾病治療市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第11章亞太卡斯爾曼疾病治療市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第12章歐洲、中東和非洲卡斯爾曼病治療市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第13章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第14章上市公司名單

第15章附錄

• 討論指南
• 關於許可證和定價

The Global Castleman Disease Treatment Market is forecasted to grow significantly, with a projected USD 285.18 million in 2023 at a CAGR of 14.65% and expected to reach a staggering USD 743.87 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Castleman Disease Treatment Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Castleman Disease Treatment Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease Type, market is studied across Multicentric Castleman's Disease and Unicentric Castleman's Disease. The Multicentric Castleman's Disease is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor, Giant Benign Lymphoma, Giant Lymph Node Hyperplasia, and Hamartoma of the Lyphatics. The Hamartoma of the Lyphatics is projected to witness significant market share during forecast period.

Based on Therapy, market is studied across Antiviral Drugs, Chemotherapy, Corticosteroids, Immunotherapy, Monoclonal Antibodies, and Radiation Therapy. The Antiviral Drugs is projected to witness significant market share during forecast period.

Based on Application, market is studied across Ambulatory Surgical Centers and Hospitals. The Ambulatory Surgical Centers is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Castleman Disease Treatment Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Castleman Disease Treatment Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Castleman Disease Treatment Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Castleman Disease Treatment Market?

4. What is the competitive strategic window for opportunities in the Global Castleman Disease Treatment Market?

5. What are the technology trends and regulatory frameworks in the Global Castleman Disease Treatment Market?

6. What is the market share of the leading vendors in the Global Castleman Disease Treatment Market?

7. What modes and strategic moves are considered suitable for entering the Global Castleman Disease Treatment Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Castleman Disease Treatment Market, by Disease Type, 2022 vs 2030
• 4.3. Castleman Disease Treatment Market, by Indication, 2022 vs 2030
• 4.4. Castleman Disease Treatment Market, by Therapy, 2022 vs 2030
• 4.5. Castleman Disease Treatment Market, by Application, 2022 vs 2030
• 4.6. Castleman Disease Treatment Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Advancement in diagnosis of castleman disease
    • 5.1.1.2. Increasing prevalence castleman disease among AIDS patients
    • 5.1.1.3. Rising awareness about castleman disease
  • 5.1.2. Restraints
    • 5.1.2.1. Premium pricing of drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Government support in research and development of orphan drugs
    • 5.1.3.2. Potential of predictive biomarker in idiopathic multicentric castleman disease
  • 5.1.4. Challenges
    • 5.1.4.1. Limited information about current clinical trials
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization
  • 5.9.1. Preferred Treatment Options

6. Castleman Disease Treatment Market, by Disease Type

• 6.1. Introduction
• 6.2. Multicentric Castleman's Disease
• 6.3. Unicentric Castleman's Disease

7. Castleman Disease Treatment Market, by Indication

• 7.1. Introduction
• 7.2. Angiofollicular Lymph Node Hyperplasia
• 7.3. Angiomatous Lymphoid
• 7.4. Castleman Tumor
• 7.5. Giant Benign Lymphoma
• 7.6. Giant Lymph Node Hyperplasia
• 7.7. Hamartoma of the Lyphatics

8. Castleman Disease Treatment Market, by Therapy

• 8.1. Introduction
• 8.2. Antiviral Drugs
• 8.3. Chemotherapy
• 8.4. Corticosteroids
• 8.5. Immunotherapy
• 8.6. Monoclonal Antibodies
• 8.7. Radiation Therapy

9. Castleman Disease Treatment Market, by Application

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Hospitals

10. Americas Castleman Disease Treatment Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Castleman Disease Treatment Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Castleman Disease Treatment Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. CASTLEMAN DISEASE TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2022 VS 2030
• FIGURE 3. CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2022 VS 2030 (%)
• FIGURE 5. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
• FIGURE 6. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2022 VS 2030 (%)
• FIGURE 7. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
• FIGURE 8. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. CASTLEMAN DISEASE TREATMENT MARKET DYNAMICS
• FIGURE 10. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CASTLEMAN DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 5. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 8. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 15. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 40. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 62. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 66. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 134. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 135. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 150. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 151. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 154. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 155. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 193. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 194. CASTLEMAN DISEASE TREATMENT MARKET LICENSE & PRICING